ATE406383T1 - Verkürzte tau proteine - Google Patents
Verkürzte tau proteineInfo
- Publication number
- ATE406383T1 ATE406383T1 AT03763763T AT03763763T ATE406383T1 AT E406383 T1 ATE406383 T1 AT E406383T1 AT 03763763 T AT03763763 T AT 03763763T AT 03763763 T AT03763763 T AT 03763763T AT E406383 T1 ATE406383 T1 AT E406383T1
- Authority
- AT
- Austria
- Prior art keywords
- molecules
- amino acids
- terminal amino
- tau
- detectable
- Prior art date
Links
- 102000013498 tau Proteins Human genes 0.000 title 1
- 108010026424 tau Proteins Proteins 0.000 title 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 2
- 102000029749 Microtubule Human genes 0.000 abstract 2
- 108091022875 Microtubule Proteins 0.000 abstract 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 2
- 210000005013 brain tissue Anatomy 0.000 abstract 2
- 210000004688 microtubule Anatomy 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT10532002 | 2002-07-12 | ||
| PCT/EP2003/007389 WO2004007547A2 (en) | 2002-07-12 | 2003-07-09 | Truncated tau proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406383T1 true ATE406383T1 (de) | 2008-09-15 |
Family
ID=30120907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03763764T ATE391781T1 (de) | 2002-07-12 | 2003-07-09 | Transgenes tier welches das trunkierte alzheimer tau protein exprimiert |
| AT03763763T ATE406383T1 (de) | 2002-07-12 | 2003-07-09 | Verkürzte tau proteine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03763764T ATE391781T1 (de) | 2002-07-12 | 2003-07-09 | Transgenes tier welches das trunkierte alzheimer tau protein exprimiert |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8288608B2 (de) |
| EP (3) | EP1521774B1 (de) |
| JP (3) | JP4308760B2 (de) |
| CN (2) | CN100572392C (de) |
| AT (2) | ATE391781T1 (de) |
| AU (2) | AU2003246664B2 (de) |
| DE (2) | DE60320258T2 (de) |
| DK (2) | DK1521774T3 (de) |
| ES (2) | ES2304146T3 (de) |
| WO (2) | WO2004007547A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2304146T3 (es) * | 2002-07-12 | 2008-09-16 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Animales transgenicos que expresan la proteina tau truncada de la enfermedad de alzheimer. |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7609947B2 (en) | 2004-09-10 | 2009-10-27 | Panasonic Corporation | Method and apparatus for coordinating playback from multiple video sources |
| KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
| KR100734815B1 (ko) | 2006-02-15 | 2007-07-09 | 대한민국 | Ｈｔａｕ24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| CN102058619A (zh) * | 2010-12-08 | 2011-05-18 | 山西医科大学 | 一种阿尔茨海默病复合动物模型的制备方法 |
| CN103476945A (zh) * | 2010-12-31 | 2013-12-25 | 宙斯科技公司 | 使用基于分子核酸的技术确定细胞活性的改进方法 |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012162179A1 (en) | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| EP2758433B1 (de) * | 2011-09-19 | 2017-10-18 | Axon Neuroscience SE | Proteinbasierte therapie und diagnose von tau-vermittelter pathologie bei morbus alzheimer |
| SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
| PT2885010T (pt) | 2012-08-16 | 2020-03-11 | Ipierian Inc | Métodos de tratamento de uma tauopatia |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| EP3104870A4 (de) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau-peptide, anti-tau-antikörper und verfahren zur verwendung davon |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| CA2966964A1 (en) | 2014-11-19 | 2016-05-26 | Michal Novak | Humanized tau antibodies in alzheimer's disease |
| EP3653712B1 (de) * | 2015-02-04 | 2022-11-30 | F. Hoffmann-La Roche AG | Tau-antisense-oligomere und verwendungen davon |
| WO2017172764A1 (en) * | 2016-04-01 | 2017-10-05 | The Regents Of The University Of California | Modified cell line and method of determining tauopathies |
| KR101997319B1 (ko) * | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용 |
| WO2018126180A1 (en) * | 2016-12-30 | 2018-07-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for the detection of tau protein aggregates |
| AU2018239433B2 (en) * | 2017-03-21 | 2024-02-01 | Indiana University Research And Technology Corporation | A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof |
| MX2020009991A (es) | 2018-03-28 | 2020-10-14 | Axon Neuroscience Se | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. |
| JP2022528953A (ja) | 2019-04-05 | 2022-06-16 | タウク３ バイオロジクス リミテッド | 抗タウｃ３抗体及びその使用 |
| CA3148740A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| CN110679549B (zh) * | 2019-11-05 | 2021-08-20 | 南通大学 | 一种阿尔茨海默病小鼠模型的构建方法 |
| IL311564A (en) * | 2021-09-24 | 2024-05-01 | Alnylam Pharmaceuticals Inc | Microtubule-associated protein tau (MAPT) iRNA compositions and methods of using them |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| AU4322999A (en) * | 1998-06-01 | 1999-12-20 | Advanced Research And Technology Institute, Inc. | Methods and compositions for diagnosing tauopathies |
| IL147406A0 (en) * | 1999-07-02 | 2002-08-14 | Janssen Pharmaceutica Nv | Transgenic animals as models for neurodegenerative disease |
| EP1214598B1 (de) * | 1999-09-09 | 2006-05-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening nach inhibitoren von "gepaarten helikalen filamenten" |
| AU2001229619A1 (en) * | 2000-01-21 | 2001-07-31 | Pharmacia And Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| AU2001241849A1 (en) * | 2000-02-29 | 2001-09-12 | Karen Duff | Transgenic mice comprising a genomic human tau transgene |
| GB0100119D0 (en) * | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| US20020164657A1 (en) * | 2001-02-23 | 2002-11-07 | Sharma Satish K. | Assays for assessing A beta-Tau aggregation |
| ES2304146T3 (es) * | 2002-07-12 | 2008-09-16 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Animales transgenicos que expresan la proteina tau truncada de la enfermedad de alzheimer. |
-
2003
- 2003-07-09 ES ES03763764T patent/ES2304146T3/es not_active Expired - Lifetime
- 2003-07-09 ES ES03763763T patent/ES2311734T3/es not_active Expired - Lifetime
- 2003-07-09 AT AT03763764T patent/ATE391781T1/de active
- 2003-07-09 JP JP2004520541A patent/JP4308760B2/ja not_active Expired - Fee Related
- 2003-07-09 DK DK03763763T patent/DK1521774T3/da active
- 2003-07-09 DE DE60320258T patent/DE60320258T2/de not_active Expired - Lifetime
- 2003-07-09 AT AT03763763T patent/ATE406383T1/de active
- 2003-07-09 CN CNB03816647XA patent/CN100572392C/zh not_active Expired - Lifetime
- 2003-07-09 EP EP03763763A patent/EP1521774B1/de not_active Expired - Lifetime
- 2003-07-09 AU AU2003246664A patent/AU2003246664B2/en not_active Expired
- 2003-07-09 US US10/521,049 patent/US8288608B2/en not_active Expired - Lifetime
- 2003-07-09 AU AU2003253044A patent/AU2003253044B2/en not_active Expired
- 2003-07-09 CN CN03816645A patent/CN100577803C/zh not_active Expired - Lifetime
- 2003-07-09 US US10/521,140 patent/US20060167227A1/en not_active Abandoned
- 2003-07-09 JP JP2004520542A patent/JP4414332B2/ja not_active Expired - Lifetime
- 2003-07-09 DE DE60323231T patent/DE60323231D1/de not_active Expired - Lifetime
- 2003-07-09 EP EP03763764A patent/EP1521831B1/de not_active Expired - Lifetime
- 2003-07-09 EP EP08014706A patent/EP1995255A1/de not_active Withdrawn
- 2003-07-09 DK DK03763764T patent/DK1521831T3/da active
- 2003-07-09 WO PCT/EP2003/007389 patent/WO2004007547A2/en active IP Right Grant
- 2003-07-09 WO PCT/EP2003/007390 patent/WO2004007722A2/en active IP Right Grant
-
2008
- 2008-12-02 JP JP2008307564A patent/JP2009143906A/ja active Pending
-
2009
- 2009-10-06 US US12/574,414 patent/US9485972B2/en active Active
-
2012
- 2012-09-14 US US13/618,946 patent/US9161520B2/en not_active Expired - Fee Related
-
2015
- 2015-09-10 US US14/850,683 patent/US20160106077A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406383T1 (de) | Verkürzte tau proteine | |
| ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
| ATE169304T1 (de) | Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung | |
| CY1106899T1 (el) | Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα | |
| ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
| ATE364698T1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
| CA2268029A1 (en) | Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments | |
| EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
| WO2006028561A3 (en) | Novel purified fabi polypeptides from fransicella tularensis | |
| DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| ATE344325T1 (de) | Neisseria lactoferrin-bindendes protein | |
| BRPI0308978A8 (pt) | fragmentos de peptídeos sintéticos ativos | |
| DE602006017806D1 (de) | Behandlung von neurodegeneration | |
| ATE346091T1 (de) | Neues diagnostisches reagens und kit zur erkennung von rickettsiose | |
| DE69712182T2 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| ATE441713T1 (de) | Tumorantigenprotein und dessen verwendung | |
| DE60321443D1 (de) | Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung | |
| SG170757A1 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
| ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| WO2001000655A3 (en) | Therapeutic peptides derived from subsequences of bpi | |
| WO2003083099A3 (en) | Purified polypeptides involved in protein synthesis and modification | |
| WO2004058811A3 (en) | Crystal structures of yhhf polypeptides | |
| WO2003095644A1 (fr) | Nouvelles proteines et adn pour lesdites proteines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1521774 Country of ref document: EP |